Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products)

重组人鼠嵌合抗CD20单克隆抗体（上海生物制品研究所）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRecombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesShanghai Institute of Biological Products Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute of Biological Products Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A